Evolus, Inc. Common Stock (EOLS) — 分析摘要
Evolus, Inc. Common Stock（EOLS）的市值为523.78百万美元，最近一年的营收同比增长了+11.6%。净利润率为-17.4%。当前市盈率为-15.3倍。
核心要点
- 营收同比变化+11.6%
- 净利润率-17.4%
- 市盈率-15.3倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，EOLS的营收增长为+11.6%，市盈率为-15.3倍。
Evolus, Inc. Common Stock (EOLS)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -1.2x — 盈利不足以覆盖利息支出
股东权益为负，可能意味着资产负债表承压。
最新报表显示自由现金流为负。
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
353
总部
NEWPORT BEACH, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。